Sugi Predict

Sugi Predict / Compounds / SCHEMBL7180289

SCHEMBL7180289

SCHEMBL7180289

COc1cc(OC)c([PH](=O)C(=O)c2c(C)cccc2C)c(OC)c1C(=O)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.40
▸ MAPT P10636 3/20 0.39
▸ HPGD P15428 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ NPC1 O15118 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ CNR2 P34972 1/20 0.37
▸ TUBB4A P04350 3/20 0.37
▸ TUBB P07437 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189353 0.92 TUBB4A (0.40) ATMMAPTHPGDLMNAKDM4E
SCHEMBL7180822 0.92 ATM (0.39) ATMMAPTHPGDLMNAKDM4E
SCHEMBL7188968 0.90 CA12 (0.42) ATMMAPTHPGDLMNAKDM4E
SCHEMBL7178026 0.89 ATM (0.37) ATMMAPTHPGDLMNAKDM4E
SCHEMBL7188320 0.88 MAPT (0.42) ATMMAPTHPGDLMNAKDM4E
SCHEMBL7187660 0.87 ATM (0.38) ATMMAPTHPGDLMNAKDM4E
SCHEMBL7182099 0.87 TUBB4A (0.43) ATMMAPTHPGDLMNAKDM4E
SCHEMBL7188965 0.85 TUBB4A (0.41) ATMMAPTHPGDLMNAKDM4E
SCHEMBL7178311 0.84 MRGPRX4 (0.39) ATMMAPTHPGDLMNAKDM4E
SCHEMBL7189016 0.83 ALDH1A1 (0.38) ATMMAPTHPGDLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ATM 2823/4885MAPT 4870/4885HPGD 3983/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ATM 2935/4885MAPT 4859/4885HPGD 4041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.